ID   BT245
AC   CVCL_IP13
SY   BT-245; BT 245; BCH245; Boston Children's Hospital 245; CPDM_0797X
DR   BTO; BTO_0005952
DR   cancercelllines; CVCL_IP13
DR   Millipore; SCC219
DR   PharmacoDB; BT245_130_2019
DR   Wikidata; Q54798426
RX   Patent=US20200384022;
RX   PubMed=25366336;
RX   PubMed=34610309;
WW   Provider; CPDM; CPDM_0797X; https://docs.google.com/spreadsheets/d/1sxAPF3p6xK2h01zaiQ1ExCWwzhxeZ-oDLN3s3LeJq98/edit?usp=sharing
CC   Part of: Center for Patient Derived Models (CPDM) at Dana-Farber Cancer Institute cell line panel.
CC   Population: Caucasian.
CC   Characteristics: Low-passage-number culture.
CC   Characteristics: Grows as neurospheres in suspension (PubMed=34610309; Millipore=SCC219).
CC   Sequence variation: Mutation; HGNC; HGNC:4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (Patent=US20200384022).
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
ST   Source(s): Millipore=SCC219
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 11
ST   D18S51: 14
ST   D21S11: 31.2
ST   D3S1358: 18
ST   D5S818: 12
ST   D7S820: 8,10
ST   D8S1179: 11,13
ST   FGA: 19
ST   Penta D: 12
ST   Penta E: 14
ST   TH01: 9
ST   TPOX: 8,12
ST   vWA: 14,15
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   8Y8M
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 10-04-25; Version: 12
//
RX   Patent=US20200384022;
RA   Suva M.L., Bernstein B.E., Regev A., Filbin M.G., Tirosh I., Hovestadt V.;
RT   "Methods and compositions for targeting developmental and oncogenic
RT   programs in H3K27M gliomas.";
RL   Patent number US20200384022, 10-Dec-2020.
//
RX   PubMed=25366336; DOI=10.1093/neuonc/nou303; PMCID=PMC4482855;
RA   Green A.L., Ramkissoon S.H., McCauley D., Jones K., Perry J.A.,
RA   Hsu J.H.-R., Ramkissoon L.A., Maire C.L., Hubbell-Engler B., Knoff D.S.,
RA   Shacham S., Ligon K.L., Kung A.L.-J.;
RT   "Preclinical antitumor efficacy of selective exportin 1 inhibitors in
RT   glioblastoma.";
RL   Neuro-oncol. 17:697-707(2015).
//
RX   PubMed=34610309; DOI=10.1016/j.celrep.2021.109788;
RA   Stockslager M.A., Malinowski S., Touat M., Yoon J.C., Geduldig J.,
RA   Mirza M., Kim A.S., Wen P.Y.-C., Chow K.-H., Ligon K.L., Manalis S.R.;
RT   "Functional drug susceptibility testing using single-cell mass
RT   predicts treatment outcome in patient-derived cancer neurosphere
RT   models.";
RL   Cell Rep. 37:109788.1-109788.12(2021).
//